Media Summary: Panelists discuss their neoadjuvant and adjuvant treatment approaches for Denise A. Yardley, MD, considers the diagnostic and prognostic workup of a 56-year-old woman who presents with Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith

Case 1 Clinical Trials In Early Stage Her2 Breast Cancer - Detailed Analysis & Overview

Panelists discuss their neoadjuvant and adjuvant treatment approaches for Denise A. Yardley, MD, considers the diagnostic and prognostic workup of a 56-year-old woman who presents with Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Dr Javier Cortes discusses results from the randomised, open-label, Recorded at the 18th Annual Perspectives in The panel discusses the decision-making process for

Sara M. Tolaney, MD, MPH, chief, Division of Comprehensive insight on adjuvant regimens used to manage Pathologist Evita Sadimin, MD, reviews current guideline recommendations for

Photo Gallery

Case 1: Clinical Trials in Early-Stage HER2+ Breast Cancer
Case 1: Approach to Early Stage, HER2+ Breast Cancer
Case 1: Treatment for Early-Stage HER2+ Breast Cancer
Case 1: Early-Stage HER2+ Breast Cancer
Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer
Early-Stage HER2+ Breast Cancer: The ATEMPT Trial
HR+ HER2- Breast Cancer Clinical Trial
Assessing a Case of Early-Stage HER2+ Breast Cancer
Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast Cancer
PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo
Early Stage HER2+ Breast Cancer - Dr. Christy Russell
Case 1: Decision Making in Early Stage HER2+ Breast Cancer
Sponsored
Sponsored
View Detailed Profile
Case 1: Clinical Trials in Early-Stage HER2+ Breast Cancer

Case 1: Clinical Trials in Early-Stage HER2+ Breast Cancer

Ian Krop, MD, summarizes key

Case 1: Approach to Early Stage, HER2+ Breast Cancer

Case 1: Approach to Early Stage, HER2+ Breast Cancer

Tiffany Traina, MD, reviews

Sponsored
Case 1: Treatment for Early-Stage HER2+ Breast Cancer

Case 1: Treatment for Early-Stage HER2+ Breast Cancer

Panelists discuss their neoadjuvant and adjuvant treatment approaches for

Case 1: Early-Stage HER2+ Breast Cancer

Case 1: Early-Stage HER2+ Breast Cancer

Ian Krop, MD, reviews the

Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer

Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer

Breast cancer

Sponsored
Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

A detailed review of the ATEMPT

HR+ HER2- Breast Cancer Clinical Trial

HR+ HER2- Breast Cancer Clinical Trial

Researchers at Rutgers

Assessing a Case of Early-Stage HER2+ Breast Cancer

Assessing a Case of Early-Stage HER2+ Breast Cancer

Denise A. Yardley, MD, considers the diagnostic and prognostic workup of a 56-year-old woman who presents with

Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast Cancer

Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast Cancer

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

Dr Javier Cortes discusses results from the randomised, open-label,

Early Stage HER2+ Breast Cancer - Dr. Christy Russell

Early Stage HER2+ Breast Cancer - Dr. Christy Russell

Recorded at the 18th Annual Perspectives in

Case 1: Decision Making in Early Stage HER2+ Breast Cancer

Case 1: Decision Making in Early Stage HER2+ Breast Cancer

The panel discusses the decision-making process for

HER2 Positive Early Stage Breast Cancer - The Breast Cancer Trials Podcast

HER2 Positive Early Stage Breast Cancer - The Breast Cancer Trials Podcast

HER2

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH, chief, Division of

Genomics In Practice: High Risk Early-Stage ER+ Breast Cancer, a Case-Based Webinar Series (2 of 3)

Genomics In Practice: High Risk Early-Stage ER+ Breast Cancer, a Case-Based Webinar Series (2 of 3)

During

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

KOLs in

Hormone Receptor Positive, HER2- Breast Cancer Clinical Trial

Hormone Receptor Positive, HER2- Breast Cancer Clinical Trial

A Single Arm

Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

Comprehensive insight on adjuvant regimens used to manage

Case 1: Guidelines for HER2 Testing in Breast Cancer

Case 1: Guidelines for HER2 Testing in Breast Cancer

Pathologist Evita Sadimin, MD, reviews current guideline recommendations for

Impact of the KATHERINE Trial on Early-Stage HER2+ BC

Impact of the KATHERINE Trial on Early-Stage HER2+ BC

Experts consider how the KATHERINE